StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK)

StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOKFree Report) in a report issued on Thursday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Trading Down 2.2 %

Shares of NASDAQ:EVOK opened at $0.47 on Thursday. The company has a market capitalization of $3.97 million, a PE ratio of -0.20 and a beta of 0.22. The business has a 50 day moving average of $0.62 and a two-hundred day moving average of $0.93. Evoke Pharma has a 12-month low of $0.42 and a 12-month high of $2.42.

Evoke Pharma (NASDAQ:EVOKGet Free Report) last announced its earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) earnings per share for the quarter. The business had revenue of $1.68 million for the quarter. Evoke Pharma had a negative return on equity of 517.99% and a negative net margin of 150.43%.

About Evoke Pharma

(Get Free Report)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Read More

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.